Cytophage Technologies Ltd. announced that it has strengthened its board of directors with the addition of John Snisarenko, a 30+ year veteran of, and seasoned C- Suite executive in, the pharmaceutical and biotech industries. During his 30+ years in pharmaceutical and biotech industries, John Snisarenko focused on ophthalmology and eye care. John's most recent position was Chief Commercial Officer for Oyster Point Pharma, where he led the launch planning, infrastructure building and commercial launch for Tyrvaya.

Prior to Oyster Point, John served as Group Vice President and Head of the Ophthalmics Franchise at Shire (now Takeda), where he led a large, multidisciplinary team in the commercialization of Xiidra. He also served as a member of the Shire Commercial Leadership Team. Previously, John was the VP & Franchise Head responsible for the commercial activities within Genentech's Ophthalmology (Lucentis) and Rheumatology (Rituxan, Actemra) franchises for 10 years.

All three medicines achieved over $1B in sales in the U.S. marketplace. John also held various positions of increasing responsibility at CIBA Vision /Novartis Pharma Canada. In his last 9 years there, he served as VP and Business Unit Head for Novartis Ophthalmics, holding general management responsibilities for the Canadian business.

John holds a B.Sc. in Biochemistry and an MBA in Marketing and International Business from McGill University in Montreal, Canada. He is currently serving as an Independent Director, Board Member and Advisor to many start-up and established companies in both Canada and the United States.